BridgeBio Pharma Inc and Eidos Therapeutics Inc at Cowen HealthCare Conference Transcript
All right (technical difficulty) equity research here. So BridgeBio has assembled a portfolio of over 20 programs spanning genetic diseases, dermatology and targeted oncology with some genetic drivers as well.
This sounds like a lot, but the portfolio is supported by a unique structure as well as the Company's strategy of jumping on science that they either have a lead on because they were willing to start earlier, or because of their connections to academia that may give them some advantage there as well. Here to tell us more today, Senior Vice President of BridgeBio, Tom Trimarchi.
All right, great, thank you. Again, Tom Trimarchi, Senior VP BridgeBio. First I want to thank all of you for being here in the room with us. I know it's the last day of what was a long and hopefully productive conference in what already feels like along week and it's only Wednesday. But really appreciate you all being here.
Before I dig into the presentation I just want to say a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
